Commonwealth Equity Services
NGEN

Commonwealth Equity Services’s NervGen Pharma NGEN Stock Holding History

Commonwealth Equity Services’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68K Sell
33,000
-350
-1% -$1.09K ﹤0.01% 4284
2026
Q1 		$126K Buy
+33,350
New +$144K ﹤0.01% 4098

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Commonwealth Equity Services's NGEN Position: Q2 2026 in Review

Commonwealth Equity Services reduced its NervGen Pharma (NGEN) stake by 1% in Q2 2026, selling an estimated $1.09K and leaving 33,000 shares worth $68K. The position accounts for ﹤0.01% of the portfolio, ranked #4284.

Commonwealth Equity Services first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $126K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Commonwealth Equity Services held 33,000 shares of NervGen Pharma worth $68K as of Q2 2026.
  • Commonwealth Equity Services sold 350 NervGen Pharma shares in Q2 2026, an estimated $1.09K.
  • NervGen Pharma made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4284 holding.
  • Commonwealth Equity Services first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Commonwealth Equity Services's NervGen Pharma position peaked at $126K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.